Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
DocuSign Q4 Fiscal 2026 Earnings Call - IAM hits scale with $350M ARR, setting stage to accelerate ARR while preserving 30%+ margins and $1B+ free cash flow
DocuSign closed fiscal 2026 with steady top-line growth and a strategic inflection: its AI-native Intelligent Agreement Management platform, IAM, reached over $350 million in ARR after 18 months and n...
- Q4 revenue $837 million, up 8% year over year, subscription revenue $819 million, also up 8% YoY.
- ARR ended at $3.3 billion, up 8% year over year; billings exceeded $1 billion in Q4, up 10% YoY, first time above $1 billion.
- IAM reached over $350 million in ARR after about 18 months, representing roughly 10.8% of company ARR, up from 2.3% at the end of fiscal 2025.
- +12 more takeaways
Titan America Q4 2025 Earnings Call - Record 2025, Keystone Acquisition to Expand Mid-Atlantic Capacity
Titan America closed 2025 with record revenue, adjusted EBITDA, net income, and operating cash flow, leaning on vertical integration, cost discipline, and stronger non-residential and infrastructure d...
- Titan delivered record full-year 2025 results: revenue $1.66 billion (up 1.8%), adjusted EBITDA $390 million (up ~5%), adjusted EBITDA margin 23.4% (up 75 basis points), and net income $185 million (up 12%).
- Q4 2025 results: revenue $406 million (up 4% year-over-year), adjusted EBITDA $94 million (up ~12%), and Q4 adjusted EBITDA margin 23.1% (vs 21.4% in Q4 2024).
- Company agreed to acquire Keystone Cement Company (Bath, PA), adding ~990,000 short tons of clinker capacity, serving a >6 million short ton addressable market across PA, OH, MD, and DE, with mineral assets supporting 50+ years of production; transaction is under regulatory review.
- +12 more takeaways
Kestra Medical Technologies Q3 FY2026 Earnings Call - 63% revenue surge as prescriptions climb and margins expand
Kestra reported a breakout quarter: revenue of $24.6 million, up 63% year over year, driven by more than 5,400 prescriptions and continued market-share gains. Management flagged ongoing operating leve...
- Revenue $24.6 million in Q3 FY2026, up 63% year over year, driven by prescription volume and higher revenue per fit.
- Kestra accepted over 5,400 ASSURE System prescriptions in the quarter, a sequential uptick management called the strongest in recent history.
- Management reported gross margin expansion for the ninth consecutive quarter and cited a gross margin of 52.6% in prepared remarks, while a conflicting line from the prepared script referenced 32.6%; company emphasis remains on steady margin improvement and a path to 70%+ over the next few years.
- +16 more takeaways
Lululemon Athletica Q4 2025 Earnings Call - Interim Team Bets on 35% Newness to Restore Full-Price U.S. Sales
Interim co-CEOs Meghan Frank and André Maestrini laid out an action plan to revive North American full-price selling, leaning on a heavy infusion of product newness, SKU rationalization, and tighter m...
- Interim co-CEOs prioritized restoring North American full-price sales, targeting a step-change in product newness, SKU reduction, and lower markdowns as the core fixes.
- Management is increasing newness penetration to approximately 35% in 2026, up from 23% in 2025, and insists that this is true new product, not just new colorways.
- Q4 revenue was $3.6 billion, up 1% reported, and excluding the 53rd week revenue rose 6% (4% on a constant currency basis); comparable sales increased 2%.
- +11 more takeaways
HealthEquity Q4 FY2026 Earnings Call - Record HSA Sales and 500bp Margin Expansion Signal Compounding Flywheel
HealthEquity closed fiscal 2026 with a clean, loud message. The company added a record 550,000 HSAs in Q4 and more than 1 million from sales for the year, lifting total accounts to 17.8 million and HS...
- Record HSA sales: Added 550,000 HSAs in Q4 and over 1 million HSAs from sales for fiscal 2026, bringing total accounts to 17.8 million.
- Assets and balances: HSA assets grew 14% year-over-year to more than $36 billion, with asset growth outpacing account growth, signaling higher balances per member.
- Strong margin expansion: Q4 adjusted EBITDA grew 23% and adjusted EBITDA margin expanded over 500 basis points to 40%; fiscal 2026 adjusted EBITDA margin was 43%.
- +12 more takeaways
IZEA Q4 2025 Earnings Call - Break-even and cash stability after strategic pivot to enterprise clients
IZEA closed 2025 having engineered a sharp pivot from SMB churn to enterprise accounts and, crucially, delivered a first-time net profit swing. Management cut operating costs roughly 40% and stabilize...
- Company achieved a net profit swing of $18.9 million in 2025 and reported break-even net income for the year, marking a turnaround from prior losses.
- Annual revenue was $31.2 million, down 13% year-over-year, reflecting a strategic pivot away from lower-margin SMB work and adverse macro factors.
- Q4 2025 revenue was $6.1 million, a 45% decline year-over-year; management says more than half of the decline resulted from intentional client rationalization.
- +10 more takeaways
Energy Vault Q4 2025 Earnings Call - Asset Vault shift drives 540 MW contracted and Q4 positive adjusted EBITDA
Energy Vault closed 2025 with a sharp operational pivot paying off. Q4 revenue surged to $153.3 million and full-year revenue reached $203.7 million, helping the company record positive adjusted EBITD...
- Q4 2025 revenue was $153.3 million; full-year 2025 revenue was $203.7 million, up over 340% year-over-year.
- Q4 GAAP gross profit was $31.6 million and full-year GAAP gross profit was $48 million, an nearly 8x improvement versus prior year.
- Full-year gross margin expanded to 23.6% in 2025 from 13.4% in 2024, driven by scale and favorable business mix.
- +13 more takeaways
Cibus Q4 2025 Earnings Call - Rice royalties and regulatory wins set up 2027 launches, runway tight into late Q3 2026
Cibus says 2025 was a turning point, citing technical gains, regulatory progress and initial commercial receipts that collectively position the company to begin royalty generation from gene-edited ric...
- Cibus calls 2025 a landmark year, driven by converging technology, commercialization, scale, and regulatory momentum.
- Seven rice customers represent a stated potential annual royalty opportunity of over $200 million, focused initially on herbicide-tolerant traits.
- Management expects initial commercial entry for rice in Latin America in 2027, U.S. expansion in 2028, and India/Asia closer to 2030.
- +12 more takeaways
ClearPoint Neuro, Inc. Q4 & Full Year 2025 Earnings Call - Tightened 2026 Guidance as FDA Rare-Disease Signals and IRRAS Integration Shift Near-Term Upside
ClearPoint closed 2025 with momentum and a newly acquired IRRAS product line, but management tightened 2026 guidance to $52 million-$56 million after factoring in recent FDA communications on rare-dis...
- 2026 guidance set to $52.0M to $56.0M, tightened to reflect recent FDA communications on rare-disease trial rigor and IRRAS integration priorities, with any positive FDA developments treated as upside.
- Full year 2025 revenue was $37.0 million, up from $31.4 million in 2024; fourth quarter revenue was $10.4 million versus $7.8 million in Q4 2024.
- Biologics and Drug Delivery revenue rose 10% to $19.0M for 2025, and increased 23% in Q4 to $5.2M, driven by higher disposable product demand from advancing partner trials.
- +12 more takeaways
Trevi Therapeutics Q4 2025 Earnings Call - FDA Aligns on Two Phase 3 Trials and Clear NDA Path for IPF-Related Chronic Cough
Trevi heads into 2026 with momentum. After positive 2025 CORAL and RIVER data, the company held a constructive end-of-phase 2 meeting with the FDA that produced a defined path to an NDA for IPF-relate...
- Trevi had two positive 2025 readouts, CORAL (IPF chronic cough) and RIVER (refractory chronic cough), that underpin the current acceleration of clinical programs.
- Following a collaborative end-of-phase 2 meeting, the FDA and Trevi agreed the primary endpoint for IPF-related chronic cough will be objective cough monitoring, and the development path toward an NDA is clear.
- Trevi will run two parallel pivotal phase 3 trials in IPF-related chronic cough: a global 52-week trial (primary efficacy at 24 weeks, ~300 patients) starting in Q2, and a confirmatory global trial (primary efficacy at 12 weeks, ~130 patients) starting in H2.
- +11 more takeaways